CXCL10 Protein (AA 22-98)

Catalog No. ABIN2666632

Product Details

Target: CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))

Protein Type: Recombinant

Biological Activity: Active

Protein Characteristics: AA 22-98

Origin: Mouse

Source: Escherichia coli (E. coli)

Application: Multiplex Assay (MA)

Purity: > 98 % , as determined by Coomassie stained SDS-PAGE.

Sterility: 0.22 μm filtered

Endotoxin Level:

Less than 0.01 ng per μg cytokine as determined by the LAL method.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Bioactivity was measured by its property to chemoattract PHA, IL-2 activated T cells in a dose dependent manner.

Restrictions: For Research Use only

Handling

Format: Liquid

Reconstitution: For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored from -20 °C to -70 °C. Stock solutions can also be prepared at 50-100 μg/mL in sterile buffer (PBS, HPBS, DPBS, or EBSS) containing carrier protein such as 0.2-1 % BSA or HSA and stored in working aliquots at -20 °C to -70 °C.

Buffer: 0.22 μm filtered protein solution is in PBS.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored between 2°C and 8°C for one month, at -20°C for six months, or at -70°C for one year.

Target Details

Target: CXCL10 (Chemokine (C-X-C Motif) Ligand 10 (CXCL10))

Alternative Name: CXCL10 (CXCL10 Products)

Background: CXCL10 is an ELR-negative chemokine structurally and functionally related to CXCL9 and CXCL11. CXCL10, CXCL9, and CXCL11 are produced and secreted by monocytes, macrophages, fibroblasts, and epithelial cells upon stimulation with proinflammatory cytokines, especially IFNγ. CXCL10 chemoattracts CD4, CD8, and NK and NKT cells through the binding to its receptor CXCR3, which is shared with CXCL9 and CXCL11. In addition, CXCL10 inhibits neovascularization in tumors and in wound healing in vivo. Also, CXCL10 has anti-proliferative effects on endothelial cells in vitro, and angiostatic and antitumor effects in vivo. It has been suggested that the anti-proliferative effect of CXCL10 in endothelial cells is CXCR3-independent and that it is mediated through GAG interaction. CXCL10 also possesses antimicrobial activity against E. coli and L. monocytogenes, and both the spore and bacillus forms of B. anthracis. CXCL10 expression is strongly upregulated in many inflammatory diseases, including arthritis, type I diabetes, experimental autoimmune encepahlomyelitis, atherosclerosis, allograft rejection, and others.

Molecular Weight: The 78 amino acid recombinant protein has a predicted molecular mass of approximately 8.8 kDa. The DTT-reduced and non-reduced protein migrate at approximately 10 kDa by SDS-PAGE. The N-terminal amino acid is Met.